ICYMI, this week we had stories about the American Society for Dermatologic Surgery Meeting, pediatric nail disorders, generalized pustular psoriasis treatment, and more.
The legacy of the late Vic Narurkar, MD, and his commitment to aesthetics was honored at the 2022 Annual ASDS Meeting.
Immune checkpoint inhibitor therapy does not appear to increase complication rates in patients undergoing dermatologic procedures, according to a video oral abstract presentation at the 2022 ASDS Annual Meeting.
Harold J. Brody, MD, provides his best tips and tricks for superficial and medium depth chemical peels in a presentation at the 2022 ASDS Annual Meeting.
Saranya Wyles, MD, PhD, takes a closer look at skin aging, cellular senescence, and emerging regenerative medicine techniques at the 2022 Annual ASDS Meeting.
Six strategies for profitability with new payment models.
A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
Patients saw improvements in the first-ever phase 3 trial of the blood therapy for the condition.
Acne, molluscum, atopic dermatitis, and other dermatological disorders can be detrimental to quality of life for children and their families.
Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide insight on when it is appropriate to switch from one biologic to another for a patient with psoriasis.
Drs Mark G. Lebwohl and Joseph F. Merola discuss the use of biosimilars in psoriasis and how biosimilars will change the treatment landscape.
In this week’s Pointers with Dr Portela, the 208SkinDoc discusses holistic medicine vs. western medicine for eczema treatment.
Catch up on coverage from the editors of Dermatology Times® who attended the annual ASDS Meeting.
A new study shows the AD drug does not interfere with vaccinations or increase severity.
Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.
Continued research and development are resulting in exciting new treatment options for major dermatological conditions.
Lack of providers, stigma are barriers to seeking needed care, but meaningful conversations can help.
Management differs from adults and requires a meticulous examination to rule out underlying diseases.
Patients with generalized pustular psoriasis flares were 2 times more likely to have emergency department visits.